# US 2022/0034890 A1 · Use of bmmf1 rep protein as a biomarker for breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034890 A1
- Document ID: US20220034890A1
- Status: Published application
- Kind: A1
- Application number: 17/444,778
- Filed: 2021-08-10
- Published: 2022-02-03
- Earliest claimed: 2019-02-22
- Applicants: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
- Inventors: Timo BUND; Ethel-Michele DE VILLIERS-ZUR HAUSEN; Harald ZUR HAUSEN; Claudia ERNST; Claudia TESSMER
- Web page: https://patentgrep.com/patent/US20220034890A1

## CPC

- G01N 33/57515: of the breast
- G01N 2333/46: from vertebrates
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the use of BMMF Rep-protein as biomarker for breast cancer.

## Claims

### Claim 1

1) A biomarker for breast cancer comprising a Bovine Meat and Milk Factor Group 1 (BMMF1) Rep Protein.

### Claim 2 (depends on 1)

2) The biomarker of claim 1 wherein the Rep protein is a MSBI1 genome-encoded Rep protein (MSBI1 Rep), a MSBI2 genome-encoded Rep protein (MSBI2 Rep), a CMI1 genome-encoded Rep protein (CMI1 Rep), a CMI2 genome-encoded Rep protein (CMI2 Rep) or CMI3 genome-encoded Rep protein (CMI3 Rep).

### Claim 3

3) A method for providing a diagnosis or predisposition for breast cancer in a subject, comprising detecting Rep protein in a sample from a subject by anti-Rep antibodies that bind to an epitope comprising SEQ ID NO:2 or SEQ ID NO:3.

### Claim 4 (depends on 3)

4) The method of claim 3, wherein the antibody specific for Rep protein binds to an epitope that is within an amino acid sequence selected from the group consisting of amino acids from 1 to 136, from 137 to 229 and from 230 to 324 of SEQ ID NO:1.

### Claim 5 (depends on 3)

5) The method of claim 3, wherein the sample from a subject is selected from the group consisting of a cancerous breast tissue, peripheral tissue surrounding the cancerous tissue, (benign) hyperplasias.

### Claim 6 (depends on 4)

6) The method of claim 4, wherein the sample from a subject is selected from the group consisting of a cancerous breast tissue, peripheral tissue surrounding the cancerous tissue, (benign) hyperplasias.

### Claim 7 (depends on 3)

7) The method of claim 3, wherein additionally CD68 positive cells are detected in the sample by an anti-CD68 antibody.

### Claim 8 (depends on 4)

8) The method of claim 4, wherein additionally CD68 positive cells are detected in the sample by an anti-CD68 antibody.

### Claim 9 (depends on 5)

9) The method of claim 5, wherein additionally CD68 positive cells are detected in the sample by an anti-CD68 antibody.
